SCHEMBL4949400

SCHEMBL4949400

CCCC[C@@]1(O)[C@H](O)[C@@H](CO)O[C@]1(n1cc(C)c(=O)[nH]c1=O)[SiH](c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TK2 O00142 7/20 0.36
RNASE1 P07998 1/20 0.35
TK1 P04183 4/20 0.34
TYMP P19971 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4952762 0.85 TK2 (0.39) TK2RNASE1TK1TYMP
SCHEMBL4470358 0.83 TK2 (0.34) TK2RNASE1TK1TYMP
SCHEMBL5668670 0.83 RNASE1 (0.37) TK2RNASE1TK1TYMP
SCHEMBL6223881 0.82 TK2 (0.33) TK2RNASE1TK1TYMP
SCHEMBL7639912 0.81 TK1 (0.34) TK2RNASE1TK1
SCHEMBL3300461 0.79 TK2 (0.38) TK2RNASE1TK1TYMP
SCHEMBL3516066 0.77 TK2 (0.32) TK2TK1
SCHEMBL7211344 0.77 PNP (0.38) TK1
SCHEMBL7156110 0.77 TK1 (0.34) TK1
SCHEMBL3696551 0.77 RNASE1 (0.36) TK2RNASE1TK1TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631235-A4 COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN ISIS PHARMACEUTICALS INC (US) 2008-05-21 EP disclosed
EP-1613728-A4 MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION ISIS PHARMACEUTICALS INC (US) 2007-07-25 EP disclosed
EP-1718762-A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2006-11-08 EP disclosed
EP-1648910-A2 ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2006-04-26 EP disclosed
EP-1633302-A2 MODULATION OF APOLIPOPROTEIN (A) EXPRESSION Isis Pharmaceuticals, Inc. (US) 2006-03-15 EP disclosed
EP-1631235-A2 COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN Isis Pharmaceuticals, Inc. (US) 2006-03-08 EP disclosed
EP-1629084-A2 MODULATION OF C-REACTIVE PROTEIN EXPRESSION Isis Pharmaceuticals, Inc. (US) 2006-03-01 EP disclosed
EP-1613728-A2 MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2006-01-11 EP disclosed
WO-2005083124-A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2005-09-09 WO disclosed
EP-1569695-A2 ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2005-09-07 EP disclosed
WO-2000036150-A1 ANTISENSE MODULATION OF ELK-1 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-22 WO disclosed
WO-2000033889-A1 ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-15 WO disclosed
WO-2000034302-A1 ANTISENSE MODULATION OF EGR-1 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-15 WO disclosed
WO-2000032818-A1 ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-08 WO disclosed
WO-2000032817-A1 ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-08 WO disclosed
WO-2000031296-A1 ANTISENSE MODULATION OF INTERLEUKIN-15 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-02 WO disclosed
WO-2000030686-A1 ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-ALPHA EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-02 WO disclosed
WO-2000031103-A1 ANTISENSE MODULATION OF MEK2 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-02 WO disclosed
WO-2000031105-A1 ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-02 WO disclosed
WO-2000031111-A1 ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2000-06-02 WO disclosed